Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Brilinta Approved by FDA

By Drug Discovery Trends Editor | July 21, 2011

WASHINGTON (AP) – A long-delayed blood thinner from AstraZeneca PLC won U.S. approval, posing new competition to the multibillion-dollar blockbuster pill Plavix.

The Food and Drug Administration said it approved Brilinta to reduce heart attacks and prevent deaths in patients with acute coronary syndrome, or clogged arteries. More than 1 million U.S. patients are hospitalized each year with heart attacks, stroke and other complications of the condition, according to the American Heart Association.

The drug works by preventing the formation of blood clots that can block blood flow to the heart. The twice-a-day tablet is designed to be used in combination with low doses of aspirin.

Twice last year, in September and December, the FDA delayed making a decision on the drug, which already is available in Europe and Canada.

An international, 18,000-patient study conducted by AstraZeneca showed that patients taking Brilinta instead of Plavix were less likely to experience various heart-related problems, including heart attack, stroke and death. The drug’s label will note that benefit, but will also contain a boxed warning that Brilinta should not be used with high-dose aspirin, which reduces its effectiveness. In company trials, U.S. patients taking the drug fared worse than patients in many foreign countries that traditionally use lower doses of aspirin.

The label will also include a box warning about bleeding side effects, which are common to most blood-thinning drugs. Roughly 11 percent of patients taking both Plavix and Brilinta experienced internal bleeding in company trials

Sanofi SA and Bristol-Myers Squibb Co.’s drug Plavix currently dominates the market for prescription blood thinners. The drug was the second best-selling pharmaceutical in the world last year, with $8.8 billion in sales. Analysts estimate Brilinta could reach sales of $1 billion by 2015.

A rival blood thinner Effient from Eli Lilly & Co. has faced an uphill climb since winning approval in 2009. The drug posted only $115 million in sales last year.

Date: July 20, 2011
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50